The efficacy and safety of sildenafil in Chinese patients with pulmonary arterial hypertension

Hypertension Research

Volumn 32, Issue 10, 2009, Pages 911-915

  Xu, Xi Qi ^a,b   Jing, Zhi Cheng ^a,c   Zhang, Jin Hu ^b   Wu, Yan ^c   Wang, Yong ^d   Jiang, Xin ^a   Wang, Zhi Xing ^b   Sun, Yin Guang ^e   Pu, Jie Lin ^c   Yang, Yue Jin ^c  

^a TONGJI UNIVERSITY   (China)

^b Aviation Industry Central Hospital   (China)

^c FUWAI HOSPITAL   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e Parkway Health Medical Centers ^*  (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BOSENTAN; SILDENAFIL;

ADULT; ARTERIAL OXYGEN SATURATION; ARTICLE; BLURRED VISION; CHINESE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ECHOCARDIOGRAPHY; FEMALE; HEADACHE; HEART CATHETERIZATION; HEART INDEX; HEART RIGHT ATRIUM PRESSURE; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHYSICAL PERFORMANCE; PREDICTION; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SKIN ALLERGY; SURVIVAL RATE; SURVIVAL TIME; TRICUSPID VALVE REGURGITATION; WALKING;

ADULT; BIOLOGICAL MARKERS; EXERCISE; EXERCISE TEST; FEMALE; HEART CATHETERIZATION; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PIPERAZINES; PULMONARY CIRCULATION; PURINES; SULFONES; SURVIVAL; VASODILATOR AGENTS;

EID: 70349978990     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2009.113     Document Type: Article

References (19)

1. Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43(Suppl 12): 5S-12S.
2. Rubin LJ. Pulmonary arterial hypertension. Proc Am Thorac Soc 2006; 3: 111-115.
3. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2008; 118: 2372-2379.
4. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT. Survival in patients with primary pulmonary hypertension: Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
5. McGoon MD. Prognostic and natural history. In: Rubin L, Rich S (eds). Primary Pulmonary Hypertension. Marcel Dekker: New York, 1997, pp 305-317.
6. Jing ZC, Xu XQ, Han ZY, Wu Y, Deng KW, Wang H, Wang ZW, Cheng XS, Xu B, Hu SS, Hui RT, Yang YJ. Registry and survival study in Chinese patients with Idiopathic and familial pulmonary arterial hypertension. Chest 2007; 132: 373-379.
7. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G. Sildenafil citrate therapy for pulmonary hypertension. N Engl J Med 2005; 353: 2148-2157.
8. Schannwell CM, Steiner S, Strauer BE. Diagnostics in pulmonary hypertension. J Physiol Pharmacol 2007; 58(Suppl 5): 591-602.
9. Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM, Simonneau G, Tapson VF, Rubin LJ. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: A 1-year follow-up study. Chest 2003; 124: 247-254.
10. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-117.
11. Tantini B, Manes A, Fiumana E, Pignatti C, Guarnieri C, Zannoli R, Branzi A, Galié N. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol 2005; 100: 131-138.
12. Wharton J, Strange JW, Møller GM, Growcott EJ, Ren X, Franklyn AP, Phillips SC, Wilkins MR. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005; 172: 105-113.
13. Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D, Archer SL. Long term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003; 108: 2066-2069.
14. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296-302.
15. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension. Circulation 2002; 105: 2398-2403.
16. Kothari SS, Duggal B. Chronic oral sildenafil therapy in severe pulmonary artery hypertension. Indian Heart J 2002; 54: 404-409.
17. Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007; 116: 1555-1562.
18. Sastry BK, Raju BS, Narasimhan C, Prakash GS, Reddy NK, Ananad B. Sildenafil improves survival in idiopathic pulmonary arterial hypertension. Indian Heart J 2007; 59: 336-341.
19. Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB, PACES Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial. Ann Intern Med 2008; 21: 521-530.